» Subscribe Today!
The Power of Information
Home
The Ledger - EST. 1978 - Nashville Edition
X
Skip Navigation LinksHome > Name & Property Search

Name & Property Search

Search results for 'Pfizer' | Search again
DeSoto Public Records:0
Shelby Public Records:93
Editorial:100
West Tennessee:0
Middle Tennessee:4
East Tennessee:0
Other:0

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

TNLedger Knoxville Edition subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again


Editorial Results (free)

1. Pfizer buying spree continues with $5.4B hematology deal -

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its work in rare hematology. Global Therapeutics, which was founded in 2011, makes Oxybryta tablets for treating sickle cell disease.

2. Pfizer buying spree continues with $5.4B hematology deal -

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease. Oxbryta sales were about $195 million last year.

3. Live on the Green announces lineup -

The lineup for Live on the Green features both local favorites and noisemaking newcomers as the Labor Day weekend music festival returns to Nashville’s Public Square Park after a two-year pandemic-related hiatus.

4. COVID-19 vaccine sales push Moderna past expectations in Q2 -

Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street's second-quarter forecasts.

The company said that its Spikevax vaccine brought in $4.53 billion during the quarter. Analysts were looking for around $3.6 billion, according to FactSet.

5. Growing prescriptions help push CVS past Q2 expectations -

CVS Health thumped second-quarter expectations and hiked its full-year forecast as growing prescription claims and COVID-19 test kits sales countered a drop in vaccinations.

A longer cough, cold and flu season also brought in more business, and claims in CVS Health's biggest segment, pharmacy benefits management, rose about 4%. Pharmacy sales at the company's established drugstores also climbed more than 7%.

6. Dolly Parton among Carnegie Medal of Philanthropy winners -

NEW YORK (AP) — Country superstar Dolly Parton, who made a big donation to help fund coronavirus vaccine research in 2020, is among this year's Carnegie Medal of Philanthropy recipients.

Also being honored are Dallas entrepreneur Lyda Hill, Kenyan industrialist Manu Chandaria, and Lynn and Stacy Schusterman, from the Oklahoma investment family.

7. US rules out summer COVID boosters to focus on fall campaign -

WASHINGTON (AP) — U.S. regulators said Friday they are no longer considering authorizing a second COVID-19 booster shot for all adults under 50 this summer, focusing instead on revamped vaccines for the fall that will target the newest viral subvariants.

8. US reaches deal with Moderna for omicron COVID-19 vaccine -

WASHINGTON (AP) — The Biden administration said Friday it has reached an agreement with Moderna to buy 66 million doses of the company's next generation of COVID-19 vaccine that targets the highly transmissible omicron variant, enough supply this winter for all who want the upgraded booster.

9. Biden tests positive for COVID-19, has 'very mild symptoms' -

WASHINGTON (AP) — President Joe Biden tested positive for COVID-19 on Thursday and is isolating with "very mild symptoms," the White House said, as new variants of the highly contagious virus challenge the nation's efforts to get back to normal after two and a half years of pandemic.

10. CDC endorses more traditional Novavax COVID shot for adults -

U.S. adults who haven't gotten any COVID-19 shots yet should consider a new option from Novavax -- a more traditional kind of vaccine, health officials said Tuesday.

Regulators authorized the nation's first so-called protein vaccine against COVID-19 last week, but the final hurdle was a recommendation from the Centers for Disease Control and Prevention.

11. Experts rue simple steps not taken before latest COVID surge -

With new omicron variants again driving COVID-19 hospital admissions and deaths higher in recent weeks, states and cities are rethinking their responses and the White House is stepping up efforts to alert the public.

12. Experts rue simple steps not taken before latest COVID surge -

With new omicron variants again driving COVID-19 hospital admissions and deaths higher in recent weeks, states and cities are rethinking their responses and the White House is stepping up efforts to alert the public.

13. Masks could return to Los Angeles as COVID surges nationwide -

LOS ANGELES (AP) — Nick Barragan is used to wearing a mask because his job in the Los Angeles film industry has long required it, so he won't be fazed if the nation's most populous county reinstates rules requiring face coverings because of another spike in coronavirus cases across the country.

14. Over-the-counter birth control? Drugmaker seeks FDA approval -

WASHINGTON (AP) — For the first time, a pharmaceutical company has asked for permission to sell a birth control pill over the counter in the U.S.

HRA Pharma's application on Monday sets up a high-stakes decision for health regulators amid legal and political battles over women's reproductive health. The company says the timing was unrelated to the Supreme Court's recent decision overturning Roe v. Wade.

15. US allows pharmacists to prescribe Pfizer's COVID-19 pill -

WASHINGTON (AP) — Pharmacists can prescribe the leading COVID-19 pill directly to patients under a new U.S. policy announced Wednesday that's intended to expand use of Pfizer's drug Paxlovid.

The Food and Drug Administration said pharmacists can begin screening patients to see if they are eligible for Paxlovid and then prescribe the medication, which has been shown to curb the worst effects of COVID-19. Previously only physicians could prescribe the antiviral drug.

16. US buys 105 million COVID vaccine doses for fall campaign -

WASHINGTON (AP) — U.S. health officials said Wednesday they have agreed to purchase another 105 million doses of Pfizer's COVID-19 vaccine in anticipation of a fall booster campaign.

The $3.2 billion deal announced by the Biden administration comes as federal scientists consider how to update the vaccines to better protect Americans from the rapidly evolving virus. Federal officials said the purchase agreement includes the option to purchase a total of 300 million doses, including a mix of doses for both adults and children.

17. US grapples with whether to modify COVID vaccine for fall -

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match recent changes of the shape-shifting coronavirus.

Moderna and Pfizer have tested updated shots against the super-contagious omicron variant, and advisers to the Food and Drug Administration will debate Tuesday if it's time to make a switch — setting the stage for similar moves by other countries.

18. Experts endorse Moderna COVID-19 shots for kids ages 6 to 17 -

NEW YORK (AP) — An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17 Thursday.

Advisers to the U.S. Centers for Disease Control and Prevention voted unanimously to recommend Moderna shots as an option for school-age kids and adolescents. This group has been able to get shots shots made by Pfizer since last year.

19. FDA advisers back Moderna's COVID-19 vaccine for older kids -

NEW YORK (AP) — A government advisory panel Tuesday endorsed a second brand of COVID-19 vaccine for school-age children and teens.

The Food and Drug Administration's outside experts voted unanimously that Moderna's vaccine is safe and effective enough to give kids ages 6 to 17. If the FDA agrees, it would become the second option for those children, joining Pfizer's vaccine.

20. Legal Aid Society picks Nashville managing attorney -

Legal Aid Society, Tennessee’s largest legal nonprofit, has hired Jordan Stringer as managing attorney and director of its Volunteer Lawyers Program.

As managing attorney, Stringer will supervise staff members, oversee administrative functions for the Nashville office, work closely with other management team members to coordinate client services and assist in oversight and quality assurance systems. Stringer will also serve as director of the Volunteer Lawyers Program, developing strategic initiatives and managing staff to support pro bono lawyers helping clients across 48 counties in Middle Tennessee.

21. US: Pfizer COVID-19 shot appears effective for kids under 5 -

WASHINGTON (AP) — Federal health officials said Sunday that kid-sized doses of Pfizer's COVID-19 vaccines appear to be safe and effective for kids under 5, a key step toward a long-awaited decision to begin vaccinating the youngest American children.

22. New vaccine may be option for troops with religious concerns -

WASHINGTON (AP) — A COVID-19 vaccine that could soon win federal authorization may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have refused other coronavirus vaccines for religious reasons.

23. FDA advisers back Novavax COVID shots as 4th US option -

American adults who haven't yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.

Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation's fourth coronavirus shot for adults. It's made with more conventional technology than today's dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option.

24. Moderna says updated COVID shot boosts omicron protection -

Moderna's experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work, the company announced Wednesday.

COVID-19 vaccine makers are studying updated boosters that might be offered in the fall to better protect people against future coronavirus surges.

25. White House: 1st shots for kids under 5 possible by June 21 -

WASHINGTON (AP) — The Biden administration said Thursday that children under 5 may be able to get their first COVID-19 vaccination doses as soon as June 21, if federal regulators authorize shots for the age group, as expected.

26. Novavax hopes its COVID shot wins over FDA, vaccine holdouts -

GAITHERSBURG, Md. (AP) — Americans may soon get a new COVID-19 vaccine option -- shots made with a more tried-and-true technology than today's versions. The big question: Why should they care?

27. Long COVID affects more older adults; shots don't prevent it -

New U.S. research on long COVID-19 provides fresh evidence that it can happen even after breakthrough infections in vaccinated people, and that older adults face higher risks for the long-term effects.

28. US making COVID antiviral drug more available at test sites -

WASHINGTON (AP) — The White House on Thursday announced more steps to make the antiviral treatment Paxlovid more accessible across the U.S. as it projects COVID-19 infections will continue to spread over the summer travel season.

29. Pfizer to offer low-cost medicines, vaccines to poor nations -

Pfizer said Wednesday that it will provide nearly two dozen products, including its top-selling COVID-19 vaccine and treatment, at not-for-profit prices in some of the world's poorest countries.

The drugmaker announced the program at the World Economic Forum's annual gathering in Davos, Switzerland, and said it was aimed at improving health equity in 45 lower-income countries. Most of the countries are in Africa, but the list also includes Haiti, Syria, Cambodia and North Korea.

30. Pfizer says 3 COVID shots protect children under 5 -

Three doses of Pfizer's COVID-19 vaccine offer strong protection for children younger than 5, the company announced Monday. Pfizer plans to give the data to U.S. regulators later this week in a step toward letting the littlest kids get the shots.

31. FDA clears COVID booster shot for healthy kids ages 5 to 11 -

U.S. regulators on Tuesday authorized a COVID-19 booster shot for healthy 5- to 11-year-olds, hoping an extra vaccine dose will enhance their protection as infections once again creep upward.

Everyone 12 and older already was supposed to get one booster dose for the best protection against the newest coronavirus variants -- and some people, including those 50 and older, can choose a second booster.

32. Biden marks COVID 'tragic milestone' in US at global summit -

WASHINGTON (AP) — President Joe Biden appealed to world leaders at a COVID-19 summit Thursday to reenergize a lagging international commitment to attacking the virus as he led the U.S. in marking the "tragic milestone" of 1 million deaths in America. He ordered flags lowered to half-staff and warned against complacency around the globe.

33. Pfizer to spend $11.6B on migraine treatment maker Biohaven -

Pfizer is starting to put its COVID-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area.

The New York vaccine and cancer drug maker said Tuesday it will use cash on hand to buy the remaining portion of migraine treatment developer Biohaven Pharmaceutical it does not already own.

34. Rare cases of COVID returning pose questions for Pfizer pill -

WASHINGTON (AP) — As more doctors prescribe Pfizer's powerful COVID-19 pill, new questions are emerging about its performance, including why a small number of patients appear to relapse after taking the drug.

35. FDA restricts J&J's COVID-19 vaccine due to blood clot risk -

WASHINGTON (AP) — U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson's COVID-19 vaccine due to the ongoing risk of rare but serious blood clots.

The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine. U.S. authorities for months have recommended that Americans get Pfizer or Moderna shots instead of J&J's vaccine.

36. Moderna first-quarter profit triples on robust vaccine sales -

COVID-19 vaccine sales helped Moderna triple its net income in a better-than-expected first quarter.

The vaccine maker said Wednesday that revenue from its coronavirus preventive shots jumped to $5.92 billion from $1.73 billion in last year's quarter, when the vaccines were debuting in most markets.

37. Pfizer tops Q1 expectations, revises 2022 forecast -

COVID-19 vaccine and treatment sales helped Pfizer breeze past Wall Street's first-quarter expectations, as the drugmaker's profit grew 61%.

The coronavirus vaccine Comirnaty brought in more than $13 billion in sales in the quarter, and the company is still trying to expand the market for the preventive shots.

38. FDA sets June meetings on COVID vaccines for youngest kids -

WASHINGTON (AP) — The Food and Drug Administration on Friday set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children, typically the final step before authorizing the shots.

39. Moderna seeks to be 1st with COVID shots for youngest children -

Moderna on Thursday asked U.S. regulators to authorize low doses of its COVID-19 vaccine for children younger than 6, a long-awaited move toward potentially opening shots for millions of tots by summer.

40. White House: Without funding US will lose COVID treatments -

WASHINGTON (AP) — For much of the past two years, America has been first in line for COVID-19 vaccines and treatments. Now, as drugmakers develop the next generation of therapies, the White House is warning that if Congress doesn't act urgently the U.S. will have to take a number.

41. Administration expands availability of COVID antiviral pill -

WASHINGTON (AP) — President Joe Biden's administration is taking steps to expand availability of the life-saving COVID-19 antiviral treatment Paxlovid, as it seeks to reassure doctors that there is ample supply for people at high risk of severe illness or death from the virus.

42. Get the latest COVID booster? It’s hard to know what to do -

Except for the anti-vax crowd – a self-thinning Darwinian herd – it’s time for some of us to consider another COVID shot. Turns out it’s more complicated than I had hoped.

Deciding on the first shots was a no-brainer. As soon as they were authorized for my age group, Geezer II, I made arrangements and twice stood in a substantial line at a Walmart to get jabbed. Other than some surprisingly potent soreness in the receiving arm after the first shot, there were no negative repercussions. And I felt bulletproof.

43. J&J suspends COVID-19 vaccine sales forecast -

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as $3.5 billion this year.

A global supply surplus and uncertainty about future demand — fueled in part by vaccine hesitancy in some developing markets — prompted the change, J&J said Tuesday. The company also reported a better-than-expected first-quarter profit and announced a dividend increase.

44. Japan approves Novavax COVID-19 vaccine -

TOKYO (AP) — Japan's health ministry on Tuesday formally approved Novavax's COVID-19 vaccine, a fourth foreign-developed tool to combat the infections as the country sees signs of a resurgence led by a subvariant of fast-spreading omicron.

45. Moderna announces step toward updating COVID shots for fall -

Moderna hopes to offer updated COVID-19 boosters in the fall that combine its original vaccine with protection against the omicron variant. On Tuesday, it reported a preliminary hint that such an approach might work.

46. Pfizer to seek COVID booster for healthy 5- to 11-year-olds -

Pfizer said Thursday it wants to expand its COVID-19 booster shots to healthy elementary-age kids.

U.S. health authorities already urge everyone 12 and older to get one booster dose for the best protection against the newest variants -- and recently gave the option of a second booster to those 50 and older.

47. Tech rebound lifts stocks on Wall Street after early slide -

A late-afternoon rebound led by technology companies helped drive stocks higher on Wall Street Thursday, lifting the market from an early slide.

The S&P 500 rose 0.4%, its first gain after a two-day slump. The benchmark index is still on pace for its first weekly loss in four weeks.

48. US experts discuss COVID boosters for the fall and beyond -

WASHINGTON (AP) — While many Americans are trying to move on with their lives after two years of the COVID-19 pandemic, U.S. health officials are debating the best way to use vaccines to stay ahead of the coronavirus.

49. US pulls GSK's COVID drug as omicron sibling dominates cases -

WASHINGTON (AP) — GlaxoSmithKline's IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday.

50. COVID outbreak 'extremely grim' as Shanghai extends lockdown -

BEIJING (AP) — The COVID-19 outbreak in China's largest metropolis of Shanghai remains "extremely grim" amid an ongoing lockdown confining around 26 million people to their homes, a city official said Tuesday.

51. End of COVID may bring major turbulence for US health care -

WASHINGTON (AP) — When the end of the COVID-19 pandemic comes, it could create major disruptions for a cumbersome U.S. health care system made more generous, flexible and up-to-date technologically through a raft of temporary emergency measures.

52. Biden receives 2nd booster, presses Congress on virus funds -

WASHINGTON (AP) — President Joe Biden called on Congress to pass billions of dollars in additional funding to fight the COVID-19 pandemic on Wednesday, as he received a second booster dose of the Pfizer vaccine a day after federal regulators approved a fourth shot for those aged 50 and older.

53. FDA OKs another Pfizer, Moderna COVID booster for 50 and up -

Americans 50 and older can get a second COVID-19 booster if it's been at least four months since their last vaccination, a chance at extra protection for the most vulnerable in case the coronavirus rebounds.

54. Moderna says its low-dose COVID shots work for kids younger than 6 -

Moderna's COVID-19 vaccine works in babies, toddlers and preschoolers the company announced Wednesday -- and if regulators agree it could mean a chance to finally start vaccinating the littlest kids by summer.

55. Moderna seeks FDA authorization for 4th dose of COVID shot -

WASHINGTON (AP) — Drugmaker Moderna asked the Food and Drug Administration on Thursday to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.

The request is broader than rival pharmaceutical company Pfizer's request earlier this week for the regulator to approve a booster shot for all seniors.

56. More than 30 companies to start making Pfizer's COVID pill -

GENEVA (AP) — Nearly three dozen companies worldwide will soon start making generic versions of Pfizer's coronavirus pill, the U.N.-backed Medicines Patent Pool that negotiated the deal said Thursday.

57. Pfizer seeking OK for 4th COVID dose for seniors -

WASHINGTON (AP) — Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors, according to a person familiar with the matter.

It would add a fourth dose to the regimen, which currently consists of a primary series of two shots, followed months later by a booster dose, in an effort to provide maximum protection to the over-65 population that has been hit hardest by the pandemic.

58. White House: Congress must act soon to replenish COVID funds -

WASHINGTON (AP) — The U.S. will soon begin to run out of money to bolster COVID-19 testing supplies and to guarantee that uninsured Americans keep getting free treatment for the virus unless Congress swiftly approves more funding, the White House warned.

59. As vaccine demand falls, states are left with huge stockpile -

As demand for COVID-19 vaccines collapses in many areas of the U.S., states are scrambling to use stockpiles of doses before they expire and have to be added to the millions that have already gone to waste.

60. EXPLAINER: Why Pfizer needs time to make COVID-19 treatment -

Pfizer's new COVID-19 treatment came with a catch when it debuted late last year: Supplies were limited, and it can take months to make the tablets.

Company leaders say they are expanding production and expect big gains in the next several months. That could help if another wave of cases develops.

61. New Biden pandemic plan: Closer to normal for the nation -

WASHINGTON (AP) — It's time for America to stop letting the coronavirus "dictate how we live," President Joe Biden's White House declared Wednesday, outlining a strategy to allow people to return to many normal activities safely after two years of pandemic disruptions.

62. Biden outlines COVID plans, says it's time to return to work -

WASHINGTON (AP) — President Joe Biden declared Tuesday that "it's time for Americans to get back to work" as he announced new efforts to allow people to return to normal activities safely after two years of pandemic disruptions.

63. COVID-19 vaccine sales push Moderna to $12B profit in 2021 -

Moderna's COVID-19 vaccine brought in nearly $7 billion in the final quarter of 2021, and the drugmaker says it has signed purchase agreements for another $19 billion in sales this year.

The vaccine maker's COVID-19 shots, which are now available in more than 70 countries, totaled $17.7 billion in sales last year, their first full year on the market.

64. EU advises further relaxing travel rules for foreigners -

BRUSSELS (AP) — European Union member countries agreed Tuesday that they should further facilitate tourist travel into the 27-nation bloc for people who are vaccinated against the coronavirus or have recovered from COVID-19.

65. S. Korea to give out rapid tests as omicron shatters record -

SEOUL, South Korea (AP) — South Korea will distribute free coronavirus rapid test kits at schools and senior care facilities starting next week as it weathers an unprecedented wave of infections driven by the fast-moving omicron variant.

66. Senate confirms Biden's FDA pick despite political divisions -

WASHINGTON (AP) — The Senate narrowly confirmed President Joe Biden's pick to lead the Food and Drug Administration on Tuesday pushing past a thicket of political controversies that threatened to derail what was initially expected to be an easy confirmation.

67. Delay ahead for Pfizer's COVID-19 vaccine for kids younger than 5 -

WASHINGTON (AP) — U.S. regulators on Friday put the brakes on their push to speed Pfizer's COVID-19 vaccine to children under 5, creating major uncertainty about how soon the shots could become available.

68. Novavax says protein vaccine works for kids as young as 12 -

Novavax announced Thursday that its COVID-19 vaccine proved safe and effective in a study of 12- to 17-year-olds.

Novavax makes a protein-based vaccine -- a different type than the most widely used shots -- that's a late arrival to the COVID-19 arsenal.

69. AstraZeneca sees $4B in COVID vaccine sales as revenue soars -

LONDON (AP) — AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time.

The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford.

70. Vaccines pushes Pfizer beyond expectations in final quarter -

COVID-19 vaccine sales boosted Pfizer earnings well past expectations in the fourth quarter, but the drugmaker is setting a lower-than-expected bar for 2022.

Pfizer debuted on Tuesday annual forecasts for both earnings and revenue that fell short of analyst expectations even as the drugmaker expects another robust year of sales from its vaccine, Comirnaty, and its new coronavirus treatment, Paxlovid.

71. AP source: US urges Pfizer to apply for 5-and-younger COVID shots -

WASHINGTON (AP) — U.S. regulators are urging drugmaker Pfizer to apply for emergency authorization for a two-dose regimen of its COVID-19 vaccine for children 6 months to 5 years old while awaiting data on a three-dose course, aiming to clear the way for the shots as soon as late February, a person familiar with the matter told The Associated Press Monday.

72. US gives full approval to Moderna's COVID-19 vaccine -

WASHINGTON (AP) — U.S. health regulators on Monday granted full approval to Moderna's COVID-19 vaccine, a shot that's already been given to tens of millions of Americans since its emergency authorization over a year ago.

73. Omicron amps up concerns about long COVID and its causes -

More than a year after a bout with COVID-19, Rebekah Hogan still suffers from severe brain fog, pain and fatigue that leave her unable to do her nursing job or handle household activities.

Long COVID has her questioning her worth as a wife and mother.

74. Will virus be 'over'? Most Americans think not: AP-NORC poll -

ATLANTA (AP) — Early in the pandemic, Ryan Wilson was careful to take precautions — wearing a mask, not really socializing, doing more of his shopping online.

75. COVID-19 booster drive is faltering in the US -

NEW YORK (AP) — The COVID-19 booster drive in the U.S. is losing steam, worrying health experts who have pleaded with Americans to get an extra shot to shore up their protection against the highly contagious omicron variant.

76. Pfizer begins testing omicron-matched COVID shots in adults -

Pfizer is enrolling healthy adults to test a reformulated COVID-19 vaccine that matches the hugely contagious omicron variant, to see how it compares with the original shots.

Pfizer and its partner BioNTech announced the study on Tuesday.

77. FDA halts use of antibody drugs that don't work vs. omicron -

WASHINGTON (AP) — COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant that now accounts for nearly all U.S. infections, U.S. health regulators said Monday.

78. J&J tops 4Q earnings forecasts but misses on revenue -

Johnson & Johnson edged past Wall Street's fourth quarter earnings expectations, helped by growing pharmaceutical sales, but revenue fell short.

The world's biggest maker of health care products also debuted a strong 2022 forecast of per-share earnings between $10.40 and $10.60. That's better than the $10.35 Wall Street had been projecting, according to FactSet.

79. Japan widens virus restrictions as omicron surges in cities -

TOKYO (AP) — Restaurants and bars will close early in Tokyo and a dozen other areas across Japan beginning Friday as the country widens COVID-19 restrictions due to the omicron variant, which has caused cases to surge to new highs in metropolitan areas.

80. Unilever won't top $68B bid for GSK consumer healthcare unit -

LONDON (AP) — Unilever, the maker of Vaseline skin care products and Dove soap, says it won't increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKline's consumer healthcare unit that was rejected last week.

81. Omicron leaves Germany on brink of recession as growth dips -

FRANKFURT, Germany (AP) — The risk of recession is looming for Germany after Europe's biggest economy shrank at the end of 2021 and as it faces a bumpy start to this year, with the rapid spread of COVID-19's omicron variant deterring people from shopping and travel and supply bottlenecks holding back manufacturers.

82. COVID-19 pill rollout stymied by shortages as omicron rages -

WASHINGTON (AP) — Two brand-new COVID-19 pills that were supposed to be an important weapon against the pandemic in the U.S. are in short supply and have played little role in the fight against the omicron wave of infections.

83. Pope on COVID vaccines says health care a 'moral obligation' -

ROME (AP) — Pope Francis suggested Monday that getting vaccinated against the coronavirus was a "moral obligation" and denounced how people had been swayed by "baseless information" to refuse one of the most effective measures to save lives.

84. FDA shortens timing of Moderna booster to 5 months -

WASHINGTON (AP) — U.S. regulators on Friday shortened the time that people who received Moderna's COVID-19 vaccine have to wait for a booster — to five months rather than six.

The two-dose Moderna vaccine is open to Americans 18 and older. The Food and Drug Administration's decision Friday means Moderna recipients are eligible for a booster after at least five months have passed since their last shot.

85. Vaccinations, tests give Walgreens a boost in first quarter -

COVID-19 vaccines and testing boosted Walgreens store sales growth to levels not seen in more than two decades, pushing the drugstore chain well above Wall Street expectations for the first quarter.

86. Omicron surge vexes parents of children too young for shots -

Afternoons with Grammy. Birthday parties. Meeting other toddlers at the park. Parents of children too young to be vaccinated are facing difficult choices as an omicron variant-fueled surge in COVID-19 cases makes every encounter seem risky.

87. CDC urges 'up to date' shots; no 'fully vaccinated' change -

WASHINGTON (AP) — U.S. health officials said Wednesday they are not changing the qualifications for being "fully vaccinated" against COVID-19, but they are urging Americans to stay "up to date" on their protection against the virus by getting booster shots when eligible.

88. Biden urges concern, not alarm as omicron rises -

WASHINGTON (AP) — President Joe Biden urged concern but not alarm Tuesday as the U.S. set new records for daily reported COVID-19 cases  and his administration struggled to ease concerns about testing shortages, school closures and other disruptions caused by the surging omicron variant.

89. Omicron upends return to US schools and workplaces -

Some school systems around the U.S. extended their holiday break Monday or switched back to online instruction because of the explosion in COVID-19 cases, while others pressed ahead with in-person classes amid a seemingly growing sense that Americans will have to learn to co-exist with the virus.

90. Why are so many vaccinated people getting COVID-19 lately? -

Why are so many vaccinated people getting COVID-19 lately?

A couple of factors are at play, starting with the emergence of the highly contagious omicron variant. Omicron is more likely to infect people, even if it doesn't make them very sick, and its surge coincided with the holiday travel season in many places.

91. Starbucks says employees must get vaccine or test weekly -

Starbucks says its U.S. workers must be fully vaccinated by Feb. 9 or face a weekly COVID testing requirement.

The Seattle-based coffee giant said Monday it was acting in response to the Occupational Safety and Health Administration, which issued a vaccine-or-test requirement for companies with more than 100 employees in November.

92. Elizabeth Holmes jury split on three of 11 fraud charges -

SAN JOSE, Calif. (AP) — The jury weighing fraud charges against former Theranos CEO Elizabeth Holmes on Monday said it is deadlocked on three of the 11 felony counts against her. Holmes is accused of duping investors and patients about a blood-testing technology that she hailed as a medical breakthrough.

93. How will pandemic end? Omicron clouds forecasts for endgame -

Pandemics do eventually end, even if omicron is complicating the question of when this one will. But it won't be like flipping a light switch: The world will have to learn to coexist with a virus that's not going away.

94. Tennessee gets first shipment of oral antiviral COVID drugs -

NASHVILLE (AP) — Tennessee has received its first shipments of oral antiviral treatments for COVID-19, the Tennessee Department of Health said on Thursday.

The U.S. Food and Drug Administration has issued an emergency use authorization for two oral COVID-19 treatments: Paxlovid by Pfizer and molnupiravir by Merck.

95. US adds Merck pill as 2nd easy-to-use drug against COVID-19 -

WASHINGTON (AP) — U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.

The Food and Drug Administration authorization of Merck's molnupiravir comes one day after the agency cleared a competing drug from Pfizer.

96. Pfizer pill becomes 1st US-authorized home COVID treatment -

WASHINGTON (AP) — U.S. health regulators on Wednesday authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home to head off the worst effects of the virus.

97. Biden pivots to home tests to confront omicron surge -

WASHINGTON (AP) — Fighting the omicron variant surging through the country, President Joe Biden announced the government will provide 500 million free rapid home-testing kits, increase support for hospitals under strain and redouble vaccination and boosting efforts.

98. Biden pledges 500M free virus tests to counter omicron -

WASHINGTON (AP) — Fighting the omicron variant surging through the country, President Joe Biden announced Tuesday that the government would provide 500 million free rapid tests, increase support for hospitals under strain and redouble vaccination and boosting efforts.

99. Israel to ban travel to US, Canada over omicron variant -

JERUSALEM (AP) — Israeli ministers on Monday agreed to ban travel to the United States, Canada and eight other countries amid the rapid, global spread of the omicron variant.

Prime Minister Naftali Bennett's office announced the decision following a Cabinet vote.

100. Moderna: Initial booster data shows good results on omicron -

Moderna said Monday that a booster dose of its COVID-19 vaccine should offer protection against the rapidly spreading omicron variant.

Moderna said lab tests showed the half-dose booster shot increased by 37 times the level of so-called neutralizing antibodies able to fight omicron.